Brokerages Set Rein Therapeutics Inc. (NASDAQ:RNTX) PT at $6.00

Shares of Rein Therapeutics Inc. (NASDAQ:RNTX) have received a consensus rating of “Hold” from the four analysts that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating on the company. The average 1-year target price among brokers that have covered the stock in the last year is $6.00.

RNTX has been the subject of a number of research reports. HC Wainwright lowered their target price on Rein Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a report on Monday, June 1st. Wall Street Zen upgraded Rein Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Weiss Ratings cut Rein Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 17th. Finally, Maxim Group began coverage on Rein Therapeutics in a report on Monday. They set a “buy” rating and a $4.00 price objective for the company.

Hedge Funds Weigh In On Rein Therapeutics

A number of large investors have recently bought and sold shares of the company. Susquehanna International Group LLP bought a new position in shares of Rein Therapeutics during the 3rd quarter worth approximately $35,000. HRT Financial LP bought a new stake in shares of Rein Therapeutics in the fourth quarter worth $38,000. Chicago Partners Investment Group LLC boosted its holdings in Rein Therapeutics by 32.2% during the first quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock worth $53,000 after purchasing an additional 10,000 shares during the last quarter. Northwestern Mutual Wealth Management Co. acquired a new position in Rein Therapeutics during the second quarter worth $68,000. Finally, Jane Street Group LLC acquired a new position in Rein Therapeutics during the fourth quarter worth $72,000. Institutional investors and hedge funds own 90.89% of the company’s stock.

Rein Therapeutics Stock Down 6.1%

Rein Therapeutics stock opened at $0.84 on Monday. The company has a 50 day moving average of $0.98 and a 200-day moving average of $1.19. Rein Therapeutics has a twelve month low of $0.83 and a twelve month high of $2.18. The stock has a market capitalization of $71.85 million, a PE ratio of -0.44 and a beta of 1.35.

Rein Therapeutics (NASDAQ:RNTX) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.30. Equities analysts anticipate that Rein Therapeutics will post -0.53 EPS for the current fiscal year.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.